p53 is a healthcare investment company based on a belief in long-term value creation.

P53’s portfolio company Arxx Therapeutics is joining forces with Oxitope Pharma to form Calluna Pharma. We are thrilled to continue this exciting journey and take part in the subsequent Series A round lead by Forbion. P53 has had the privilege to work with the Arxx team over time as the first investors - together with Sarsia - back in 2019. The merger, and subsequent Series A round is a considerable validation of the science and hard work that has been done by the team over the years. 
 
This deal epitomizes what we seek to accomplish in p53: to contribute to the development and commercialization of ground-breaking ideas that transform people’s lives, increase accessibility to cutting-edge treatments and innovative healthcare solutions and create exceptional value for patients.
 
We look forward to work with partners - established and new - to contribute to the success of Calluna Pharma.

Jonas Hallén Jörg Klingelhöfer Berte Poulsson Sylvia Vetrhus Kjell Skappel Oystein Soug Sarsia Investinor Susanne Stuffers, MD PhD Erlend Skagseth Sveinung Hole Farzad Abdi-Dezfuli Birgitte Gangmark Villmo Kari Grønås (prev. Dyvik) Dr. Christian Schweiger MD PhD Yuri Khodjamirian, CFA Rizwan I. Hussain Advokatfirmaet Schjødt

P53

NO:P53

p53